Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Med (New York, N.Y.)|December 17, 2024
If it is a solid tumor target, then it may be a hematologic cancer target: Bridging the great divideJacob J Adashek, Javier L Munoz, Razelle KurzrockCurrent Oncology Reports|May 21, 2022
BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing PartnerJavier L Munoz, Yucai Wang, Preetesh Jain, et al.Clinical Epigenetics|March 4, 2023
Clinical advances in epigenetic therapies for lymphomaAllison C Rosenthal, Javier L Munoz, J C VillasboasBlood Advances|August 15, 2023
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 studyAdam J Olszewski, Tycel J Phillips, Marc S Hoffmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2025
Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical StudiesFrederick L Locke, Javier L Munoz, Michael T Tees, et al.Mayo Clinic Proceedings|June 5, 2026
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026Sameer A Parikh, Paul J Hampel, Lindsey E Roeker, et al.American Journal of Hematology|September 3, 2025
Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed TherapiesSuheil Albert Atallah-Yunes, Chijioke C Nze, Rebecca L King, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.Blood Advances|February 17, 2022
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphomaJoselle Cook, Kah-Whye Peng, Thomas E Witzig, et al.Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.Pageof 2